Douglas Rahn, MD
Radiation Oncology · Chula Vista, CANPI 1609018340
Payments from drug & device makers
Across 35 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$146
- Caris MPI, Inc.$112
- AstraZeneca$110
- Regeneron Healthcare Solutions, Inc.$84
- KARL Storz Endoscopy-america$59
- Daiichi Sankyo Inc.$56
- plus $417 from 15 others
What the payments were for
- Food & beverage$984100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $146 |
| Caris MPI, Inc. | 3 | $112 |
| AstraZeneca(2 entities) | 5 | $110 |
| Regeneron Healthcare Solutions, Inc. | 3 | $84 |
| KARL Storz Endoscopy-america | 2 | $59 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Sanofi | 1 | $48 |
| Pfizer | 2 | $38 |
| AbbVie | 1 | $35 |
| Deciphera Pharmaceuticals Inc. | 1 | $32 |
| Eisai Inc. | 1 | $31 |
| Tersera Therapeutics LLC | 1 | $28 |
| Beigene USA, Inc. | 1 | $28 |
| Genmab U.S., Inc. | 1 | $26 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Bayer | 1 | $16 |
How this compares
$984 in reported general payments places this provider in the 55th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 77 | $666 |
| SsdSilver Sulfadiazine | 15 | $278 |
| Oxybutynin Chloride | 11 | $124 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Chula Vista
- Loren Mellla Jolla$10M
- Hyun KimDuarte$6M
- Megan DalyOrange$4.5M
- Percy LeeIrvine$2.4M
- Felix FengSan Francisco$1.8M
- Jeffrey WongDuarte$1.7M
- Arta MonjazebSacramento$1.5M
- Rakesh PatelLos Gatos$1.3M
- Maximilian DiehnStanford$1.2M
- Rizwan NuraniApple Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.